SCHEMBL3267243

SCHEMBL3267243

CCc1nc2c(c(=O)n(Cc3ccc(Cl)cc3)c(=O)n2CC(N)=O)n1C

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 4/20 0.48
LMNA P02545 4/20 0.47
TSHR P16473 2/20 0.47
POLB P06746 2/20 0.47
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
HIF1A Q16665 2/20 0.43
RAB9A P51151 1/20 0.43
ADORA2A P29274 2/20 0.43
ADORA2B P29275 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
ADORA1 P30542 1/20 0.43
MEN1 O00255 1/20 0.43
ALOX12 P18054 1/20 0.43
KMT2A Q03164 1/20 0.43
P2RX3 P56373 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3110981 0.90 MAPT (0.48) HTTGAAMAPTLMNATSHR
SCHEMBL3224112 0.89 MAPT (0.48) HTTGAAMAPTLMNATSHR
SCHEMBL3234639 0.89 MAPT (0.55) HTTGAAMAPTLMNATSHR
SCHEMBL3221667 0.88 MAPT (0.46) HTTGAAMAPTLMNATSHR
SCHEMBL13940722 0.88 POLB (0.52) HTTGAAMAPTLMNATSHR
SCHEMBL13940720 0.87 MAPT (0.51) HTTGAAMAPTLMNATSHR
SCHEMBL3238173 0.87 MAPT (0.55) MAPTLMNATSHRPOLBTP53
SCHEMBL3228639 0.86 ALDH1A1 (0.48) HTTGAAMAPTLMNATSHR
SCHEMBL3235070 0.85 MAPT (0.44) HTTGAAMAPTLMNATSHR
SCHEMBL4097269 0.85 MAPT (0.46) HTTGAAMAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2146996-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT AstraZeneca AB (SE) 2010-01-27 EP disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023704-A1 Novel Compounds 737 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed
WO-2008130314-A1 XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT ASTRAZENECA AB (SE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023704-A1 Novel Compounds 737 GRPR, GABRB1, GABBR1 HTT 4508/4885GAA 836/4885MAPT 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.